Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Maze Therapeutics, Inc.NASDAQ: MAZE
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.45, compared with -$0.75 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.75.
Context
- EPS (Basic) increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$2.8 (+8.2%) for the fiscal year ending Dec 2026, a step up from the -4020.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.45+48.3% QoQ
- Last fiscal yearDec 2025
- -$3.05-4020.3% YoY
- LTMMar 2026
- -$2.75-4396.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +39.9% | +6.8% | -33.0 pp |
| 1 year | -4020.3% | +8.2% | +4028.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (3.05) USD
- Year-over-year change
- -4020.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.05) | -4020.3% |
| FY2024 | 2024-12-31 | 0.08 | +103.4% |
| FY2023 | 2023-12-31 | (2.29) | +12.6% |
| FY2022 | 2022-12-31 | (2.63) | — |
EPS (Basic) vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -4396.9% is the lowest of 8, against a peer median of -10.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.24 USD | -5.0% | — | |
| LTM Jun 2026 | -$0.49 USD | -106.1% | — | |
| LTM Mar 2026 | -$0.71 USD | -10.9% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$1.29 USD | +14.6% | — |
| LTM Sep 2026 | -$1.56 USD | -48.6% | — | |
| FY2025 | -€1.82 EUR | +48.6% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$2.4 USD | -18.2% | — |
| LTM Mar 2026 | -$2.75 USD | -4396.9% | — | |
| Peer median (excluding MAZE) | — | -10.9% | — | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.